Brenipatide (LY3537031) is Eli Lilly's investigational dual agonist of the GLP-1 and GIP receptors. Its late-stage trials target alcohol use disorder and major depressive disorder rather than obesity. We found no published human efficacy results.

What is brenipatide?

It is a long-acting peptide that activates the same two receptors as tirzepatide. Secondary sources describe a once-monthly schedule. Lilly's trial pages do not state the interval, so treat that detail as secondhand.

Which brenipatide trials are registered?

Trial	Condition	Phase
RENEW-ALC-1 (NCT07219966)	Moderate-to-severe alcohol use disorder	3
RENEW-ALC-2 (NCT07219953)	Alcohol use disorder	3
Two registered studies	Major depressive disorder	3
RENEW-Op-1 (NCT07420283)	Opioid use disorder	2

Each alcohol study lists 1,100 participants and an estimated April 2028 primary completion. Lilly's RENEW-ALC-2 page lists sites in the US, Belgium, China, Japan, South Korea, Taiwan and the UK, not Australia.

Does a trial record mean supply?

No. A registry entry describes a study, not availability or the contents of any vial. See our COA guide.

Research use only

Peptide Labs supplies research peptides strictly for in-vitro laboratory use, not for human or animal use. This article reports public research and gives no use or dosing guidance.

What Is Brenipatide? Lilly's Dual GIP/GLP-1 Agonist